What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Cholesterol
The scientist’s investigation covers issues in Internal medicine, Endocrinology, Cholesterol, Apolipoprotein B and Lipoprotein.
He combines subjects such as Diabetes mellitus and Cardiology with his study of Internal medicine.
His Endocrinology study frequently draws connections between related disciplines such as Inflammation.
In the field of Cholesterol, his study on Cholesterylester transfer protein overlaps with subjects such as High density.
Within one scientific family, Philip J. Barter focuses on topics pertaining to Cell adhesion molecule under Apolipoprotein B, and may sometimes address concerns connected to Umbilical vein, Phospholipid and In vivo.
His Lipoprotein study integrates concerns from other disciplines, such as Oxidative stress and Endothelium.
His most cited work include:
- Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels (4595 citations)
- Intensive lipid lowering with atorvastatin in patients with stable coronary disease. (2894 citations)
- Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. (2495 citations)
What are the main themes of his work throughout his whole career to date?
Philip J. Barter focuses on Internal medicine, Endocrinology, Cholesterol, Lipoprotein and Apolipoprotein B.
His Internal medicine research integrates issues from Diabetes mellitus, Type 2 diabetes and Cardiology.
Philip J. Barter combines topics linked to Inflammation with his work on Endocrinology.
The study incorporates disciplines such as Pharmacology and Risk factor in addition to Cholesterol.
His Lipoprotein research incorporates elements of Chromatography and Blood plasma.
His Apolipoprotein B research includes themes of Apolipoprotein E, Hepatic lipase, In vivo and Phosphatidylcholine.
He most often published in these fields:
- Internal medicine (75.83%)
- Endocrinology (56.13%)
- Cholesterol (34.93%)
What were the highlights of his more recent work (between 2014-2021)?
- Internal medicine (75.83%)
- Endocrinology (56.13%)
- Cholesterol (34.93%)
In recent papers he was focusing on the following fields of study:
Philip J. Barter spends much of his time researching Internal medicine, Endocrinology, Cholesterol, Diabetes mellitus and Cardiology.
His research on Internal medicine often connects related topics like Type 2 diabetes.
His research in Endocrinology focuses on subjects like ABCA1, which are connected to Carbohydrate metabolism, Beta cell and Proinflammatory cytokine.
The Cholesterol study combines topics in areas such as Adverse effect and Niacin.
His research in the fields of Metabolic syndrome overlaps with other disciplines such as Risk assessment.
His work on Acute coronary syndrome, Coronary artery disease and Myocardial infarction as part of general Cardiology research is frequently linked to Mace, thereby connecting diverse disciplines of science.
Between 2014 and 2021, his most popular works were:
- Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease (337 citations)
- Dysfunctional HDL and atherosclerotic cardiovascular disease (317 citations)
- Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel (171 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Enzyme
Internal medicine, Cholesterol, Endocrinology, Cholesterylester transfer protein and Diabetes mellitus are his primary areas of study.
In his research on the topic of Internal medicine, Lipoprotein is strongly related with Cardiology.
His Cholesterol research includes elements of mir-223 and Disease.
His Apolipoprotein B, Obesity and Normal glucose tolerance study, which is part of a larger body of work in Endocrinology, is frequently linked to Content distribution, bridging the gap between disciplines.
His studies in Cholesterylester transfer protein integrate themes in fields like Monoclonal antibody and Niacin.
His work on Type 2 diabetes and Type 2 Diabetes Mellitus as part of his general Diabetes mellitus study is frequently connected to Peroxisome proliferator-activated receptor alpha, thereby bridging the divide between different branches of science.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
